首页> 外文OA文献 >PND116 - A THREE MONTH INTERIM ANALYSIS OF FINGOLIMOD TREATMENT ADHERENCE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UK: THE PATIENT REPORTED OUTCOMES WITH FINGOLIMOD IN LOCAL EXPERIENCE (PROFILE) STUDY

【2h】

PND116 - A THREE MONTH INTERIM ANALYSIS OF FINGOLIMOD TREATMENT ADHERENCE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UK: THE PATIENT REPORTED OUTCOMES WITH FINGOLIMOD IN LOCAL EXPERIENCE (PROFILE) STUDY

机译：PND116 - 一种三个月的临时分析Fingolimod治疗粘附在英国复发多发性硬化：患者在局部经验中向Fingolimod报告的结果（概况）研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
NE Adlard; J Watson; CJ Bottomley; M Kroes;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. High treatment adherence, satisfaction, motivation, and health-related quality of life with fingolimod in patients with relapsing-remitting multiple sclerosis – results from a 24-month, multicenter, open-label Danish study [J] . Karen Schreiber, Matthias Kant, Claudia Pfleger, Patient Preference and Adherence . 2018 ,第1期

机译：芬戈莫德对复发缓解型多发性硬化症患者的治疗依从性，满意度，动机和与健康相关的生活质量–一项为期24个月，多中心，开放标签的丹麦研究的结果
2. Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15. [J] . Doggrell SA Expert opinion on pharmacotherapy . 2010 ,第10期

机译：口服芬戈莫德用于复发缓解型多发性硬化症的评估：Kappos L，Radue E-M，O'Connor P等。口服芬戈莫德治疗复发性多发性硬化症的安慰剂对照试验。 N Engl J Med 2010; 362：387-401;和Cohen JA，Barkhof F，Comi G等。口服芬戈莫德或肌内干扰素可复发多发性硬化症。新英格兰医学杂志2010; 362：402-15。
3. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study [J] . Weinstock-Guttman Bianca, Medin Jennie, Khan Nasreen, CNS drugs . 2018 ,第1期

机译：在常规临床实践中，评估延迟多发性硬化患者患者的“无疾病活动证据证明疾病活动”的状态：对美国（MS-MRIUS）研究的多发性硬化临床和磁共振成像结果的回顾性分析
4. High treatment adherence satisfaction motivation and health-related quality of life with fingolimod in patients with relapsing-remitting multiple sclerosis – results from a 24-month multicenter open-label Danish study [O] . Karen Schreiber, Matthias Kant, Claudia Pfleger, 2018

机译：芬戈莫德对复发缓解型多发性硬化症患者的治疗依从性满意度动力和健康相关的生活质量–一项为期24个月多中心开放标签的丹麦研究的结果
5. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study) [O] . Comi, G, Patti, F, Rocca, Ma, 2017

机译：芬戈莫德和干扰素β-1b对复发缓解型多发性硬化症认知，MRI和临床结果的疗效：一项为期18个月的开放标签，盲目，随机，多中心研究（GOLDEN研究）

PND116 - A THREE MONTH INTERIM ANALYSIS OF FINGOLIMOD TREATMENT ADHERENCE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UK: THE PATIENT REPORTED OUTCOMES WITH FINGOLIMOD IN LOCAL EXPERIENCE (PROFILE) STUDY

著录项

相似文献

相关主题

期刊订阅